Zacks Research upgraded shares of Obsidian Therapeutics (NASDAQ:OBX – Free Report) to a hold rating in a research report report published on Thursday,Zacks.com reports.
OBX has been the topic of a number of other reports. Piper Sandler started coverage on Obsidian Therapeutics in a research report on Wednesday. They issued an “overweight” rating and a $42.00 price target on the stock. TD Cowen began coverage on Obsidian Therapeutics in a report on Thursday. They set a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.
Check Out Our Latest Report on Obsidian Therapeutics
Obsidian Therapeutics Trading Down 3.0%
Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.
Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.
Recommended Stories
- Five stocks we like better than Obsidian Therapeutics
- MarketBeat Week in Review – 08/03 – 08/07
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
Receive News & Ratings for Obsidian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obsidian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
